Timeline
Puretech Health
PureTech's Seaport advances GlyphAgo into Phase 2 after positive Phase 1 multiple‑dose data
Seaport Therapeutics prices $254.9m Nasdaq IPO, London-listed PureTech gets a lift
Seaport Therapeutics appoints Intra‑Cellular founder Sharon Mates to board
PureTech posts positive Phase 1b LYT-200 data and will prioritise relapsed/refractory high‑risk MDS
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.